Medication Monitor



Generic Name (Trade Name—Company)
Notes
January 31, 2019

Sumatriptan 10-mg nasal spray

(Tosymra—Dr. Reddy's Laboratories)
FDA approves sumatriptan 10-mg nasal spray

FDA has approved Tosymra, a new dosage formulation of sumatriptan 10 mg as a single-dose nasal spray for acute treatment of migraine with or without aura in adults. 

The spray is formulated using a proprietary novel excipient known as Intravail to achieve blood levels similar to a 4-mg sumatriptan S.C. injection, resulting in rapid onset of action.

The recommended dose is 10 mg given as a single spray in one nostril. The maximum cumulative dose that may be given in a 24-hour period is 30 mg, with doses separated by at least 1 hour. The agent may also be given at least 1 hour following a dose of another sumatriptan product.

The most common adverse effects are tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation.